321 results about "Renal filtrate" patented technology

Catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present technology, for example, is directed to a treatment device having a multi-electrode array configured to be delivered to a renal blood vessel. The array is selectively transformable between a delivery or low-profile state (e.g., a generally straight shape) and a deployed state (e.g., a radially expanded, generally helical shape). The multi-electrode array is sized and shaped so that the electrodes or energy delivery elements contact an interior wall of the renal blood vessel when the array is in the deployed (e.g., helical) state. The electrodes or energy delivery elements are configured for direct and / or indirect application of thermal and / or electrical energy to heat or otherwise electrically modulate neural fibers that contribute to renal function or of vascular structures that feed or perfuse the neural fibers.

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention provides an early-stage automatic identification method and system for acute kidney injury related to cardiac surgery, and relates to the technical field of physiological parameter detection. The method comprises the following steps: acquiring average arterial pressure, cardiac blood discharge volume, central venous pressure and blood oxygen saturation, regularly recording and extracting data of adjacent time points, calculating a variation range, screening a mutation region, judging whether a reference range is exceeded or not, analyzing a multi-parameter synchronous variation condition, and marking a hemodynamics abnormal state. According to the method, abnormal changes of hemodynamics and urine metabolism are accurately recognized through real-time monitoring and multi-parameter analysis, the urine flow rate and the metabolite excretion rate are combined, misjudgment of a single index is avoided, the fineness of renal function change analysis is improved, the high-risk time period is accurately positioned through time cross comparison, the diagnosis accuracy is improved, and the diagnosis accuracy is improved. Trend analysis and risk grade division enable the change of the illness state to be more visual, and a real-time early warning system effectively monitors the fluctuation trend, optimizes clinical management and improves the timeliness of medical response.

Computer-implemented methods of predicting the QTc of a subject in response to administration of QTc prolonging drugs, especially those that are dose adjusted for renal function, such as antiarrhythmic drugs. Included is a method of administering an antiarrhythmic drug to a subject, comprising: providing as inputs into a treatment management application i) Baseline QTc and ii) at least a Creatinine Clearance, Weight, Age, Sex, or Heart Rate; the treatment management application providing as an output one or more predicted QTc or predicted QTc range for the subject expected from administration of a 1-5 hour IV dose, alone or followed by one or more oral doses, of an antiarrhythmic drug to the subject; and upon the one or more QTc or QTc range being within an acceptable range, administering the 1-5 hour IV dose to the subject optionally followed by administering one or more of the oral doses to the subject.

The invention discloses an acute aortic syndrome early warning method, system and device and a storage medium, and belongs to the technical field of medical image processing. The method comprises the steps that an aorta CT image is acquired and preprocessed; generating a CTA image by using the cascade generative adversarial network model; and carrying out key information feature extraction on the CTA image by using a deep learning classification model DenseNet, and outputting an aortic syndrome classification result. According to the method, the high-quality CTA image can be generated without using a contrast agent, the risk possibly generated by contrast agent examination of a patient is reduced, and the method is particularly suitable for patients with renal function impairment or contrast agent allergy; compared with the prior art, an economical and efficient alternative scheme is provided, dependence on traditional CTA examination equipment and professionals is reduced, meanwhile, the accuracy rate and the timeliness rate of early warning of the acute aortic syndrome can be effectively increased, and remarkable clinical application value and social benefits are achieved.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicine. The invention provides an application of an RNF130 activator in preparation of a medicine for preventing or treating renal ischemia-reperfusion injury, the RNF130 activator can improve the renal function of a mouse suffering from renal ischemia-reperfusion injury, improve the levels of serum creatinine, urea nitrogen and cystatin C, reduce the levels of kidney injury markers KIM-1 and LCN2, reduce renal tubule injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and the renal function of the mouse suffering from renal ischemia-reperfusion injury. Therefore, the compound plays a role in preventing and treating the kidney ischemia reperfusion injury, and a new target is provided for preparing the medicine for preventing and treating the acute kidney injury.

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.

The invention relates to the technical field of medical data analysis, in particular to a kidney injury prediction system based on big data, which comprises a physiological data processing module, a fluctuation analysis construction module, a dynamic weight evaluation module, a cross-domain data scheduling module and a risk trend prediction module. According to the method, through timestamp standardization and continuous recombination of the acute kidney injury physiological data, the consistency of multi-source monitoring data in the time dimension is ensured, drifting and dislocation are eliminated, the time sequence integrity is improved, fluctuation points of serum creatinine and urine volume are extracted, sensitive time slices are recognized, and high-risk time point early warning is achieved; a rate change comparison mechanism is introduced, a physiological factor weight sequence is generated, factor influence evaluation is enhanced, uploading frequency and a time delay state are combined, high-reliability nodes are screened, data continuity and real-time performance are improved, index trend deviation is tracked, a mode label is generated, and timeliness and accuracy of renal function change prediction are improved.

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

The invention provides a method and a system for predicting an Alport syndrome through a multi-modal retina image based on deep learning, and relates to the technical field of deep learning. According to the method, a retina image, an OCT image and clinical text data are fused, a dual-channel deep neural network of an image encoder and a text encoder is constructed, semantic alignment pre-training is carried out by adopting multi-modal contrast learning, and an adversarial sample enhancement mechanism is introduced to improve model robustness; unified standardized training of different device images is achieved through the style migration module, the occurrence probability and the renal function progress risk level are finally output, and high-reliability prediction under the cross-modal and cross-device condition is achieved.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention relates to the technical field of medicines, and particularly discloses a compound antihypertensive pharmaceutical composition. The pharmaceutical composition provided by the invention selects sacubitril valsartan sodium and indapamide as active ingredients, and within a prescription dosage range limited by the application, the two medicines can fully realize an antihypertensive effect through a synergistic effect, and the renal function of a patient is effectively improved. Through cooperation of the two components, the hypertension symptom of a patient can be effectively controlled, the adverse reaction is not obvious, and the compliance of the patient can be improved by adopting the compound preparation, so that the control on the blood pressure of the patient is enhanced.

The invention relates to a weight loss intervention method and device for chronic renal failure and obesity patients based on an individualized prescription. The method comprises the following steps: constructing a multi-modal dynamic time sequence feature vector of a patient; identifying and quantifying potential causal effects of different weight loss intervention measures on physiological outcomes of renal functions, electrolyte balance, anemia states, bone mineral metabolism and weight indexes of the CKD patient according to a dual robust estimator; dynamically constructing a weight loss intervention measure causal model according to the potential causal effect of the physiological outcome of each patient and the physiological and pathological background; and inputting the multi-modal dynamic time sequence feature vector of the patient into a weight loss intervention measure causal model, and generating a daily diet scheme, an exercise scheme and corresponding high-confidence risk early warning and causal explanation of the patient. The method overcomes the limitation that the traditional method only pays attention to correlation and cannot clearly determine the intervention effect, ensures that the causal atlas and the intervention scheme are optimized according to the real-time change state of the patient, and realizes a real dynamic prescription.

The invention relates to application of 4-GBA in preparation of a medicine for improving infection endurance capacity of a sepsis patient, 4-GBA is used for treating mice infected with sepsis, compared with control mice, the survival rate of the mice treated by the 4-GBA is far larger than that of the control mice, and experiments prove that the 4-GBA has a protection effect on sepsis infection. The mechanism of 4-GBA for improving infection endurance capacity of sepsis patients is researched, and after 4-GBA treatment, the content of liver and kidney functional markers in peripheral blood serum of mice infected with sepsis is remarkably reduced, the content of DAMPs (injury related molecular patterns) related molecules in peripheral blood serum of mice infected with sepsis is remarkably reduced, and the application of 4-GBA in the treatment of the mice infected with sepsis in the treatment of the infection endurance capacity of the patients infected with sepsis in the treatment of the infection endurance capacity of the patients infected with sepsis in the treatment of the patients infected with sepsis in the treatment of the patients infected with sepsis. And the product does not have in-vivo and in-vitro sterilization functions and body immune regulation functions. The result shows that 4-GBA can improve the infection endurance capacity of the sepsis patient, and provides a new direction and a new drug for treatment of the sepsis patient.

The invention relates to the technical field of medical treatment, in particular to an intelligent general surgery preoperative risk assessment system which comprises a data acquisition module, a data fusion and processing module, a feature extraction module, a risk assessment module, a prediction and optimization module and a visual display module. The data fusion and processing module adopts a multi-modal data fusion algorithm to generate a patient comprehensive information model, the feature extraction module extracts cardiovascular health status, renal function and tumor marker key features, and the risk assessment module constructs a preoperative risk assessment model to generate a preoperative risk score; the prediction and optimization module predicts the risk of postoperative complications, and the visual display module displays an evaluation result and a prediction result in real time through a graphical interface; according to the method, the accuracy and scientificity of preoperative risk assessment and postoperative complication prediction are remarkably improved, and reliable support is provided for postoperative management of patients.

The invention relates to the technical field of data processing, and discloses an old-age multi-organ function decline rehabilitation prediction method and system based on artificial intelligence. The method comprises the following steps: screening cardiovascular, respiratory, renal function and liver function indexes of an elderly patient through a multi-source data quality evaluation matrix, carrying out time sequence synchronization according to visceral organ physiology time delay characteristics, adopting a visceral organ function correlation positioning analysis algorithm to identify a collaborative decline mode and calculating 1-NN similarity and Max-NN correlation decline degree, and finally, inputting target patient data into a special prediction model of a corresponding hierarchical group to generate a rehabilitation prediction result. According to the method and the device, the technical problem that an existing senile multi-organ function decline prediction method lacks parameter-free collaborative decline mode recognition and individualized layered prediction is solved.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The present invention relates to means and methods for modifying renal function in a subject, comprising selecting a patient requiring an increment in renal function; emitting a quantity of ultrasound radiation, enough to provide an increment in renal function, to at least one part of a kidney for a period of time from about 1 hours to about 30 days.

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.

The invention relates to the field of medical treatment, in particular to application, a model and a method of a protein fragment of urine regulatory protein in preparation of a kidney disease early detection product, and the amino acid sequence of the protein fragment of the urine regulatory protein is any shown in SEQ ID NO.1-8. The model constructed according to the protein fragment of the urine regulatory protein can be used as a non-invasive tool for early detection and monitoring of kidney diseases, and by analyzing the unique mode of the protein fragment existing in a urine sample, the model which indicates renal insufficiency, renal function and renal function can be identified before the traditional clinical biomarker is abnormal. Therefore, intervention can be carried out earlier.

The invention discloses an aza-four-membered ring connected pyrazolopyridine compound or pharmaceutically acceptable salt and application thereof, and the compound with the structure can be used as a novel high-selectivity PDE10A inhibitor for treating peripheral tissue diseases such as cardiac hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal function impairment and renal fibrosis. Lung inflammation and pulmonary fibrosis, immune regulation disorder and cancers (colon cancer, ovarian cancer and lung cancer). Through strategies in two aspects, the inhibition effect of the compound on a PDE10A high-selectivity inhibitor is reduced while the inhibition effect of the compound on a central nervous system is reduced. Firstly, in the aspect of molecular structure modification, the structure of the pyrazolopyridine compound connected with the aza-four-membered ring is optimized, for example, the polar surface area of molecules is increased by increasing the proportion of the number of N, O and S atoms in the molecular structure, and the fat solubility is reduced; and hydrophilic groups are introduced to increase water solubility and the like, so that the permeability of the compound to the blood brain barrier BBB is reduced. And 2, targeted drug delivery of lung tissues is realized by means of a pharmaceutical preparation.

The invention provides a traditional Chinese medicine composition for treating chronic kidney diseases and a preparation method and application thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 16 to 24 parts of astragalus membranaceus, 24 to 36 parts of poria cocos, 24 to 36 parts of motherwort herb, 16 to 24 parts of herba pyrolae, 24 to 36 parts of hairyvein agrimony, 24 to 36 parts of herba ardisiae japonicae, 16 to 24 parts of dianthus superbus, 16 to 24 parts of cluster mallow fruit and 6.4 to 9.6 parts of tetrapanax papyriferus. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention can safely and effectively improve the renal function of patients suffering from chronic kidney diseases such as qi deficiency, blood stasis and damp turbidity accumulation, relieve clinical symptoms and delay disease progression, and a traditional Chinese medicine scheme with an exact curative effect is provided for clinically treating the diseases.

The invention discloses a kidney function prediction method and device, electronic equipment and a medium. The method comprises the steps that a kidney cortical medullary enhancement period image of a target patient is acquired; inputting a kidney cortical medullary enhancement stage image of the target patient into the trained segmentation model to segment a cortical region in the cortical medullary enhancement stage image to obtain a cortical region image of the kidney of the target patient; extracting radiation group features of the cortex region image; and inputting the radiation group features of the cortex region image into the trained renal function staging prediction model, and predicting the renal function staging of the target patient. The invention assesses renal function by a non-invasive and reliable alternative method.

The invention provides a traditional Chinese medicine composition for treating urolithiasis. Specifically, the invention provides a traditional Chinese medicine composition consisting of glechoma longituba, semen plantaginis, pyrrosia lingua, radix achyranthis bidentatae, radix paeoniae alba, radix puerariae and honey-fried licorice root. The traditional Chinese medicine composition is simple in formula and exact in clinical curative effect. The composition is used for treating urolithiasis, can effectively relieve kidney crystallization and renal tubule injury and improve the renal function, and has the application prospect in the field of urolithiasis treatment.

The invention provides processed rhizoma polygonati polysaccharide, a preparation method thereof and application of the processed rhizoma polygonati polysaccharide in preparation of a medicine for treating renal injury. The nine-processed polygonatum sibiricum polysaccharide is named as NPCP and is composed of fructose and glucose, the NPCP is straight-chain inulin type polysaccharide with the polymerization degree of 12, and the structure of the NPCP is Glcp-(1-) and Fruf-(2-terminal,-1)-Fruf-(2-main chain. According to the obtained uniform nine-process polygonatum polysaccharide NPCP, the protective effect on adenine-induced HK-2 cell injury is achieved by improving the content of renal function markers, improving oxidative stress injury, reducing expression of proinflammatory cytokines, improving intestinal flora disorder and up-regulating short-chain fatty acid in the intestinal tract; more treatment directions are provided for effectively improving adenine-induced renal toxicity by the nine-process polygonatum polysaccharide, and theoretical and experimental bases are provided for clinically finding effective preparation of drugs for treating renal injury.

The invention discloses a traditional Chinese medicine and probiotic composition and application thereof, and belongs to the technical field of medicines. The composition is prepared from a traditional Chinese medicine extract and lactobacillus brevis DMU22441 (the preservation number is CGMCC No.65301), wherein the traditional Chinese medicine extract is prepared from fructus gardeniae, rhizoma phragmitis and flos sophorae according to the mass ratio of 1: 1: 1. The traditional Chinese medicine extract is prepared through an ethanol extraction method, and the viable count of probiotics is 10 < 9 > CFU / day. According to the composition, through a three-in-one synergistic mechanism of inhibiting synthesis, promoting excretion and regulating flora, the serum uric acid level is remarkably reduced, renal function impairment is improved, and intestinal flora imbalance is regulated. The invention provides an efficient and safe multi-target solution for the treatment of hyperuricemia and complications thereof, and has significant clinical application value.

The invention discloses an AKI, CKD and AKI-CKD progress general prediction model based on plasma proteomics and a construction method thereof. The construction method comprises the following steps: selecting a patient which has plasma proteomics data when a baseline which meets the inclusion standard of a research group, has eGFR greater than or equal to 60mL / min / 1.73 m < 2 > when the baseline exists, and has no AKI or CKD medical history; collecting clinical prediction factors and blood proteomics data of the modeling crowd; and randomly dividing the selected modeling crowd data into a training set and a verification set, screening out protein prediction markers such as protein WFDC2 and protein GDF15 shared with the development of the AKI, the CKD and the AKI-CKD, and establishing a general prediction model for the development of the AKI, the CKD and the AKI-CKD. Proteomics is used for predicting AKI-CKD progress for the first time, three renal function outcomes can be predicted at the same time, prediction indexes are simple and easy to obtain, and the model is a universal model with high prediction capacity.

Apparatus, systems, and methods for achieving thermally-induced renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a thermal element to a renal artery via an intravascular path. Thermally-induced renal neuromodulation may be achieved via direct and / or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.